IDEMIA
14.12.2020 10:32:12 CET | Business Wire | Press release
IDEMIA:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005279/en/
Security and convenience at the heart of the Icelandic project
By 2022, new EU-EES regulations will require that biometric data, including face and fingerprints, of Third Country Nationals (TCNs) be captured and identified at the Schengen Area’s external borders. This will affect border check processes for all Schengen Member States.
With 20%-a-year air traffic growth (prior to COVID-19), Iceland planned to implement a program to manage increased passenger flows primarily in Iceland’s main international airport Keflavik, where 95% of the country’s largely non EU arriving and exiting passengers pass, and also in the country’s 30 seaports defined as external sea border crossing points. The new border management systems and equipment will also contribute to inland control within the Schengen Area.
Iceland, innovation partner in border management
IDEMIA will leverage its best-in-class biometric and border control expertise to uphold and upgrade Iceland’s border security. Meanwhile, this cutting-edge technology will contribute to more secured external borders and optimize the passenger flow by the use of the newest technology in border management.
This new border management system, based on IDEMIA’s Augmented Borders™ solution, will be compliant with EU-EES regulations. IDEMIA will also equip Icelandic border crossing points with its TravelKiosk™ EU-EES, the latest generation of user-centric multi-biometric border self-service kiosks . Also including automated TraveLane™ eGates, the entire system will boost throughput and convenience of passengers as they go through border controls. Lastly, to complete this end-to-end solution, IDEMIA will ensure that operator-manned counters, mobile solutions and tracking systems are set up to fit the requirements of the Icelandic Police with a view to shortening response times and improving coordination.
“The National Commissioner of the Icelandic Police, the Metropolitan Police and Sudurnes District police have from early 2019 been working on the implementation of EES in Iceland in close cooperation with Isavia. The procurement procedure started in September 2019 and today we have reached an important milestone by selecting IDEMIA as the supplier and future partner for the implementation of EES in Iceland. The police and Isavia place a high expectation to the collaboration with IDEMIA in the development of solutions that will improve border security and the traveler experience,” said Jón Pétur Jónsson , Chief Superintendent, at the National Commissioner of the Icelandic Police.
“ Isavia is truly excited about this co-operation with IDEMIA and the Icelandic Police. This is an important step in improving the performance and customer experience of the convenient and easy hub connection between Europe and North America, ” says Guðmundur Daði Rúnarsson , Chief Commercial and Airport Development Officer at Isavia. “ The Entry Exit system will affect all airports with traffic crossing external borders. Isavia is confident that implementing IDEMIA’s self service solutions in co-operation with the border police, will result in a more secure and efficient border crossing point, giving Keflavik the potential to grow even further in its Hub operation. ”
“IDEMIA is proud to accompany Iceland as one of the first countries of the Schengen Area to transform its border control system to comply with the European Entry/Exit System. We are determined to provide a comprehensive set of multi-biometric solutions that will give the assurance of a future-proof program, making Iceland our innovation partner in the implementation of the EU-EES. Our advanced border management solutions, based on a 40-year relationship with governments, will offer a better user experience by interactively adapting the border process per traveler category, while ensuring maximum security,” said Philippe Barreau , Executive Vice President for Public Security & Identity activities at IDEMIA.
As world leader in government identity and police biometric systems, IDEMIA brings to the table its cutting-edge technology and know-how so that personal identity is checked in the most secure way.
Recently, IDEMIA, in partnership with Sopra Steria, was selected to roll out the shared Biometric Matching System - the new European automated multi-biometric identification system for foreign nationals hosted by EU agency eu-LISA. Having partnered with EU institutions for many years and installed border control systems in more than 23 countries, IDEMIA’s comprehensive package meets the complex requirements of border control authorities, topped off by state-of-the-art technology.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com or follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
